drugset / Trial / NCT02107378

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

NCT02107378

Phase 2 Terminated 22 enrolled SOTIO a.s.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).

Timeline

Start
2014-01
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject STAPULDENCEL Vaccine
Comparator Doxorubicin Other / unclassified
Comparator Paclitaxel Small molecule
Comparator Topotecan Small molecule